0 calificaciones0% encontró este documento útil (0 votos)
286 vistas5 páginas
This document provides an overview and table of contents for a book about drugs and medicines. It includes 10 chapters covering various topics related to rational drug use, essential medicines, marketing and promotion of drugs, clinical trials, patents and trade, pricing and availability of drugs, and the impacts of medicines on women's health. It also contains profiles of 50 drugs in Section 2 and short profiles of 107 drugs in Section 3 for reference purposes. The document aims to educate readers about appropriate drug use and policy through analyzing different aspects of the pharmaceutical industry and drug development, regulation, and access.
Descripción original:
Contents of the Book and Index of the Drug Profiles in Sections 2 and 3.
Título original
Contents and List of Drug Profiles in the book Lay Person's Guide to Medicines
This document provides an overview and table of contents for a book about drugs and medicines. It includes 10 chapters covering various topics related to rational drug use, essential medicines, marketing and promotion of drugs, clinical trials, patents and trade, pricing and availability of drugs, and the impacts of medicines on women's health. It also contains profiles of 50 drugs in Section 2 and short profiles of 107 drugs in Section 3 for reference purposes. The document aims to educate readers about appropriate drug use and policy through analyzing different aspects of the pharmaceutical industry and drug development, regulation, and access.
Copyright:
Attribution Non-Commercial (BY-NC)
Formatos disponibles
Descargue como PDF, TXT o lea en línea desde Scribd
This document provides an overview and table of contents for a book about drugs and medicines. It includes 10 chapters covering various topics related to rational drug use, essential medicines, marketing and promotion of drugs, clinical trials, patents and trade, pricing and availability of drugs, and the impacts of medicines on women's health. It also contains profiles of 50 drugs in Section 2 and short profiles of 107 drugs in Section 3 for reference purposes. The document aims to educate readers about appropriate drug use and policy through analyzing different aspects of the pharmaceutical industry and drug development, regulation, and access.
Copyright:
Attribution Non-Commercial (BY-NC)
Formatos disponibles
Descargue como PDF, TXT o lea en línea desde Scribd
Foreword to earlier version 5 Preface to earlier version 6 Acknowledgments 6 How to use this book 8 Index of Drug Profiles 11
Section 1
Chapter 1: About Drugs in General 15
1. Drug Forms and Administration 6 2. Evaluation of Drug Profiles 19 Annexure 1 Some Common Drug Categories and How they Work 47 Annexure 2 Poisoning and its Treatment 87
Chapter 2: Essential Drugs 92
1. Why We Need Only Essential Drugs? 93 2. Why an Essential Medicines List? 96 3. Generic/Brand Names, Innovator Products and Generics 101 4. Implementation of Essential Drugs Idea in Two States of India 112 Annexure 1 Criteria for Withdrawal of Irrational and Hazardous Drugs: the Bangladesh Example 115 Annexure 2 Access to Medicines: How India Stands Globally? 117 Annexure 3 Country Specific Approaches to Updating Essential Drugs and Formulary Lists 119 Annexure 4 Right Brands; Wrong Medicines Dietary Salt Dispensed in Place of Epilepsy Drug 120
Chapter 3: Rationality of Drugs 122
1. What is Rational Therapy? 123 2. Causes of Irrationality 129 3. Combination Drugs: When Drug Combinations are Rational 139 4. Vitamins and Tonics 5. Hazardous Drugs 143 Annexure 1 Why Some Leading Drugs in the Indian Market should not be sold - but are still sold 154 Annexure 2 Dubious FDCs Being Marketed in India … not Approved by DCGI and hence Illegal 160 Annexure 3 List of Drugs Prohibited for Manufacture and Sale through Gazette Notifications 162 Annexure 4 Identification of Harmful, Irrational and Useless Analgesics 165 Annexure 5 Irrational Combinations of Paracetamol 167 Annexure 6 Rofecoxib, Heart Attacks and the FDA: Testimony of David J. Graham 169
Chapter 4: Marketing of Drugs 178
1. Pharma Scenario in India 178 2. Marketing of Top 300 Drugs in India: A Brief Analysis 181 3. Marketing of Drugs and the Abandoning of Quality and Ethics 188 4. Manipulating Quality 192 9 5. Prevalence of Spurious Drugs 194 Annexure 1 Landmark Incidents in the Unethical Marketing of Drugs 201
Chapter 5: Drug Promotion, Clinical Trials and Conflicts of Interest 208
1. "Forms of Entanglement" 208 2. Clinical Trials, Research Publications and Conflicts of Interest 217 3. Conflicts of Interest and Codes of Marketing 231 Annexure 1 What are Clinical Trials? 235 Annexure 2 Conflict of Interest: My Journey 239 Annexure 3 WHO Ethical Criteria and IFPMA Code of Pharmaceutical Marketing Practices 241
Chapter 6: Patents, Trade and Availability of Medicines 247
1. Free Trade, WTO/TRIPS and the Pharma Industry 248 2. India, Patents and TRIPS 258 3. Possible Impacts 271 4. What is to be done? 279 Annexure 1 TRIPS in WTO: Is it Logical? 284 Annexure 2 Openness Promotes Growth? 285 Annexure 3 For Free Trade in Ideas 285 Annexure 4 Unfairness of Free Trade: WTO, a Neutral Arbiter? 287 Annexure 5 Some of the Useful Recommendations in the CIPIH Report 290
Chapter 7: Pricing and Availability of Drugs 299
1. Need for Price Control 299 2. Health and Political Context of Price Control 311 3. Some Positive Initiatives and Reports 318 4. How much do Drug Formulations Actually Cost and can Cost 324 Annexure 1 Pricing and Price Control of Drugs and Pharmaceuticals 326
Chapter 8: Women and Medicines 333
1. Medicines and Women's Health 333 2. Misuse of Drugs and its Effects on Women 337 3. Contraceptive Drugs and Women 341 4. Hormonal Replacement Therapy (HRT) 347 5. Other Concerns 348
Chapter 9: What is to be done? 356
Section 2 Profiles of 50 Drugs 363
Section 3 Short Profiles of 107 Drugs 505 Section 4 583 Primary and Secondary Information Sources on Drugs & Related Health Issues 583 Glossary 593 About LOCOST 597 About All-India Drug Action Network 598 10 Index of Drug Profiles